{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-001539","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.556575+00:00","generated_at":"2026-06-06T04:49:07.589119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug","bullets":["Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.","Cash and equivalents $4.3M at Dec 31, 2023; working capital $3.4M.","Secured up to C$23M from Canadian government for EB05 ARDS Phase 3; regulators approved harmonized US/Canada trial.","Planning Phase 2 for vitiligo (anti-CXCL10 mAb) and pulmonary fibrosis (EB05); seeking partnerships for dermatitis candidate EB01."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-001539","json":"https://secwatch.observer/filing/0001654954-24-001539.json","markdown":"https://secwatch.observer/filing/0001654954-24-001539.md","text":"https://secwatch.observer/filing/0001654954-24-001539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/0001654954-24-001539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:49:07.589119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93f465de8be362175561ab228d880aa07ef53b3a","claim":"Edesa Biotech, Inc. reported the three months ended December 31, 2023 results: net income a net loss of $1.7 million, or $0.54 per common share, EPS $0.54 per common share.","evidence_excerpt":"Edesa reported a net loss of $1.7 million, or $0.54 per common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/0001654954-24-001539-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"a net loss of $1.7 million, or $0.54 per common share"},{"label":"EPS","value":"$0.54 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}